The present disclosure relates to colloidal
drug aggregates (CDAs) that are further embedded in hydrogels for sustained local delivery. Preferred drugs include beta-blocker prodrugs and ROCK inhibitors for use in treating
glaucoma. In particularly preferred embodiments, the CDAs comprise prodrugs of
timolol or netarsudil in combination with
phospholipid stabilizers. Preferred hydrogels include hyaluronan crosslinked using an
oxime bond.